Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly in the last three months of 2024, compared the same period one year before. In a earnings report ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...

The FDA said on its website: “FDA has required and approved safety labeling changes to the prescribing information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

compared to patients receiving chemotherapy with or without bevacizumab (60.9% vs. 40.0%). Also Read: Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges The results ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and its stock remained flat after market open. Pfizer reported $63.6 ...

The Novartis study was specifically in patients who had received prior novel hormonal therapy (NHT) before the mCRPC stage and randomized them to receive a switch of NHT or Pluvicto. The Pfizer ...

Of patients on BRAFTOVI plus cetuximab and mFOLFOX6 ... View the full Prescribing Information. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our ...

With a market cap of $151.6 billion, Pfizer serves millions of patients globally ... of the securities mentioned in this article. All information and data in this article is solely for ...